BridgeBio Oncology Therapeutics, Inc. (BBOT) Live Share Price, Invest From India

BridgeBio Oncology Therapeutics, Inc. Stock Performance

as on May 13, 2026 at 6:59 am IST

Day's Low
$7.67
Day's Price Range
$8.12
$8.12
5.54%
Downside
52 Week's Low
52 Week's High
$7.60
52-Week Price Range
$14.87
$8.12
6.40%
Downside
83.13%
Upside

BridgeBio Oncology Therapeutics, Inc. share price movements today

Previous Close: $7.89
Open: $7.86
Volume: 476.9K
Day's Low - High: $7.67 - $8.12
52 Week Low - High: $7.60 - $14.87

BridgeBio Oncology Therapeutics, Inc. Historical Returns

1 Month Return: -6.07 %
3 Month Return: -30.91 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

BridgeBio Oncology Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check BridgeBio Oncology Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$613.7M

EPS (TTM)

-2.075

Dividend Yield

0.00%

PE Ratio (TTM)

PEG Ratio

Return On Equity TTM

-48.23%

BridgeBio Oncology Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of BridgeBio Oncology Therapeutics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
BridgeBio Oncology Therapeutics, Inc.	NA	$613.7M	NA	NA	0.00%
Alnylam Pharmaceuticals Inc	BUY	$39.4B	113.59%	74.13	12.55%
BeiGene, Ltd.	NA	$32.2B	NA	70.46	8.94%
Vertex Pharmaceuticals Inc	BUY	$109.1B	104.61%	25.51	35.51%
Regeneron Pharmaceuticals Inc	BUY	$74.9B	40.55%	17.45	29.65%

Indian Investors' Interest in BridgeBio Oncology Therapeutics, Inc. Stock

Search interest for BridgeBio Oncology Therapeutics, Inc. Stock has increased by 160% in the last 30 days, reflecting an upward trend in search activity.

Time period: April 13, 2026 to May 13, 2026

Change:160% versus previous 30 day period

BridgeBio Oncology Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	-	-	0	-	-	-	-	0
Operating Income	-15	-23	-19	-21	-23	-30	-49	-43
EBITDA	-15	-23	-19	-21	-23	-29	-49	-43
Interest Expense	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0
Income Before Tax	-15	-21	-17	-19	-22	-28	-44	-38
Income Tax Expense	-	-	-	-	-	-	-	-
Net Income	-15	-21	-17	-19	-22	-28	-44	-38
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

BridgeBio Oncology Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-
Gross Profit	-	-	0
Operating Income	-64	-80	-145
EBITDA	-64	-80	-145
Interest Expense	-	-	-
Depreciation	0	0	0
Income Before Tax	-64	-74	-134
Income Tax Expense	-	-	-
Net Income	-64	-74	-134
Net Profit Margin	0.00%	0.00%	0.00%

BridgeBio Oncology Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	0	-15	2	-17	1	0	-28	-44	12
Operating Cash Flow	-	-8	0	-39	0	0	-23	-70	-42
Investing Cash Flow	-	2	-	37	-	-	9	65	7
Financing Cash Flow	-	6	199	19	0	0	18	383	0
Change in Cash	-	0	0	0	0	0	5	408	-35

BridgeBio Oncology Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	0	0	7	-134
Operating Cash Flow	-	-52	0	-113
Investing Cash Flow	-	-	-184	73
Financing Cash Flow	-	55	186	383
Change in Cash	-	0	1	342

Insights on BridgeBio Oncology Therapeutics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

NEGATIVE IMPACT
Price Dip
In the last 1 month, BBOT stock has moved down by -11.8%

About BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Organisation	BridgeBio Oncology Therapeutics, Inc.
Headquarters	256 East Grand Avenue, South San Francisco, CA, United States, 94080
Industry	Biotechnology
CEO	Dr. Pedro J. Beltran M.D., Ph.D.
E-voting on shares	Click here to vote

Key Management of BridgeBio Oncology Therapeutics, Inc.

Name	Title
Mr. Daniel Watson Ph.D.	Senior Vice President of Chemistry, Manufacturing & Controls
Dr. Neil Kumar Ph.D.	Executive Chairman
Dr. Yong Ben M.B.A., M.D.	Chief Medical & Development Officer
Mr. Marc Cobo	VP of Finance & Controller
Mr. Aaron Chan J.D.	Vice President of Legal
Mr. Rui Xu Ph.D.	Senior Vice President of Drug Discovery
Dr. Frank P. McCormick Ph.D.	Co-Founder, Non-Executive Director & Chair of the Advisory Board
Dr. Pedro J. Beltran M.D., Ph.D.	Chief Executive Officer and Director
Mr. Idan Elmelech M.A., M.B.A.	Chief Operating Officer
Mr. Bin Wang Ph.D.	Senior Vice President of Drug Discovery

FAQs

What is BridgeBio Oncology Therapeutics, Inc. share price today?

BridgeBio Oncology Therapeutics, Inc. share price today is $8.12 as on May 13, 2026 at 1:29 am IST at the close of the market. BridgeBio Oncology Therapeutics, Inc. share today touched a day high of $8.12 and a low of $7.67.

What is the 52 week high and 52 week low for BridgeBio Oncology Therapeutics, Inc. share?

BridgeBio Oncology Therapeutics, Inc. share touched a 52 week high of $14.87 on December 8, 2025 and a 52 week low of $7.6 on May 7, 2026. BridgeBio Oncology Therapeutics, Inc. stock price today i.e. May 13, 2026 at 1:29 am IST is closed at $8.12,which is 45.39% down from its 52 week high and 6.84% up from its 52 week low.

What is BridgeBio Oncology Therapeutics, Inc.'s market capitalisation today?

BridgeBio Oncology Therapeutics, Inc. market capitalisation is $0.00T as on May 13, 2026 at 1:29 am IST.

How to invest in BridgeBio Oncology Therapeutics, Inc. Stock (BBOT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for BridgeBio Oncology Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in BridgeBio Oncology Therapeutics, Inc. Shares that will get you 0.1847 shares as per BridgeBio Oncology Therapeutics, Inc. share price of $8.12 per share as on May 13, 2026 at 1:29 am IST.

What is the minimum amount required to buy BridgeBio Oncology Therapeutics, Inc. Stock (BBOT) from India?

Indian investors can start investing in BridgeBio Oncology Therapeutics, Inc. (BBOT) shares with as little as ₹95.618 or $1 (as of May 13, 2026 at 6:36 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹956.18 in BridgeBio Oncology Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on May 13, 2026 at 6:36 am IST). Based on BridgeBio Oncology Therapeutics, Inc. share’s latest price of $8.12 as on May 13, 2026 at 1:29 am IST, you will get 1.2315 shares of BridgeBio Oncology Therapeutics, Inc.. Learn more about fractional shares .